Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma.
Tanguy Y SeiwertSophie WildsmithJérôme FayetteKevin HarringtonMaura GillisonMyung-Ju AhnShunji TakahashiJared WeissJean-Pascal MachielsShrujal BaxiValerie BakerBrent EvansNassim Morslinull Jill WalkerKatia RealAnne L'HernaultAmanda PsyrriPublished in: Cancer immunology, immunotherapy : CII (2024)
bTMB demonstrated potential utility for selecting patients with R/M HNSCC who benefited from durvalumab with or without tremelimumab versus EXTREME. Trial registration ClinicalTrials.gov identifier NCT02551159.